Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127805791 | 12780579 | 1 | I | 20160913 | 20160926 | 20160926 | EXP | US-PFIZER INC-2016431855 | PFIZER | DESAI, A.. TOXICITIES OF BUSULFAN/MELPHALAN VERSUS CARBOPLATIN/ETOPOSIDE/MELPHALAN FOR HIGH-DOSE CHEMOTHERAPY WITH STEM CELL RESCUE FOR HIGH-RISK NEUROBLASTOMA. BONE MARROW TRANSPLANTATION. 2016;51(9):1204-1210 | 0.00 | C | Y | 0.00000 | 20160926 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127805791 | 12780579 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | UNK | D | 76517 | ||||||||||
| 127805791 | 12780579 | 2 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | UNK | D | 0 | ||||||||||
| 127805791 | 12780579 | 3 | SS | MELPHALAN | MELPHALAN | 1 | UNK | D | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127805791 | 12780579 | 1 | Neuroblastoma |
| 127805791 | 12780579 | 2 | Neuroblastoma |
| 127805791 | 12780579 | 3 | Neuroblastoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127805791 | 12780579 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127805791 | 12780579 | Venoocclusive liver disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |